Reditrex

Active Ingredient(s): Methotrexate
FDA Approved: * November 27, 2019
Pharm Company: * CUMBERLAND PHARMS
Category: Cancer

Methotrexate (MTX), formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant.[4] It is used to treat cancer, autoimmune diseases, and ectopic pregnancy and for medical abortions.[4] Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma.[4] Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Reditrex 7.5 mg/.3ml Subcutaneous Injection, Solution
NDC: 66220-807
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 10 mg/.4ml Subcutaneous Injection, Solution
NDC: 66220-810
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 12.5 mg/.5ml Subcutaneous Injection, Solution
NDC: 66220-812
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 15 mg/.6ml Subcutaneous Injection, Solution
NDC: 66220-815
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 17.5 mg/.7ml Subcutaneous Injection, Solution
NDC: 66220-817
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 20 mg/.8ml Subcutaneous Injection, Solution
NDC: 66220-820
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 22.5 mg/.9ml Subcutaneous Injection, Solution
NDC: 66220-822
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 25 mg/ml Subcutaneous Injection, Solution
NDC: 66220-825
Labeler:
Cumberland Pharmaceuticals Inc.
Reditrex 7.5 mg/.3ml Subcutaneous Injection, Solution
NDC: 69605-807
Labeler:
Cenexi - Bla
Reditrex 10 mg/.4ml Subcutaneous Injection, Solution
NDC: 69605-810
Labeler:
Cenexi - Bla